Key facts
- This page summarizes Eldon C. Mayer III's Form 4 filing for Eiger BioPharmaceuticals, Inc..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 11 Jan 2022, 19:59.
Eldon C. Mayer III - 07 Jan 2022 Form 4 Insider Report for Eiger BioPharmaceuticals, Inc.
- Issuer symbol
- N/A
- Report date
- 07 Jan 2022
- Net transaction value
- -$7,722
- Form type
- 4
- Accepted by SEC
- 11 Jan 2022, 19:59:29 UTC
- Previous filing
- 30 Jul 2021
- Next filing
- 11 Mar 2022
- SEC filing
- View on sec.gov
- Reporting owner signature
- /s/ Sriram Ryali, Attorney-in-Fact
Source evidence
5 source fields
Reporting owner
1 detail
Key filing fact
Eldon C. Mayer III filed Form 4 for Eiger BioPharmaceuticals, Inc. on 11 Jan 2022.
Change
- Previous filing in this sequence was filed on 30 Jul 2021.
- Current net transaction value: -$7,722.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EIGR
transaction
Common Stock
Sale
- Transaction value
- $7,722
- Shares
- -1,560
- Change %
- -3.3%
- Price
- $4.95
- Shares after
- 46,125
- Date
- 07 Jan 2022
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units granted on January 31, 2020 for 7,500 shares.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.95 to $5.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.